The use of chemotherapy in patients with advanced malignant pleural mesothelioma: A systematic review and practice guideline

Journal of Thoracic Oncology

Volumn 1, Issue 6, 2006, Pages 591-601

  Ellis, Peter ^a   Davies, Angela M ^b   Evans, William K ^a   Haynes, Adam E ^a   Lloyd, Nancy S ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Advanced mesothelioma; Chemotherapy; Pleural mesothelioma; Practice guideline; Systematic review

Indexed keywords

AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; ANTHRACYCLINE DERIVATIVE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; FOLIC ACID; GEMCITABINE; IFOSFAMIDE; IMIDAZOLECARBOXAMIDE; IMMUNOMODULATING AGENT; IPROPLATIN; IRINOTECAN; MITOMYCIN; MITOXANTRONE; MYCOBACTERIUM VACCINE; NAVELBINE; OXALIPLATIN; PEMETREXED; PLATINUM DERIVATIVE; RALTITREXED; SRL 172; TAXANE DERIVATIVE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; QUINAZOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ADVANCED CANCER; BLOOD TOXICITY; BRAIN TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG FATALITY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LEUKOPENIA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYCOBACTERIUM VACCAE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHLEBITIS; PLEURA MESOTHELIOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SKIN TOXICITY; STATISTICAL SIGNIFICANCE; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION; CANCER INVASION; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; FEMALE; MALE; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; META ANALYSIS; MORTALITY; PATHOLOGY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PLEURA TUMOR; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS, PHASE II; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUTAMATES; GUANINE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; NEOPLASM INVASIVENESS; PATIENT SELECTION; PLEURAL NEOPLASMS; PRACTICE GUIDELINES; PROGNOSIS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; THIOPHENES; TREATMENT OUTCOME;

EID: 33846327132     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200607000-00017     Document Type: Review

References (133)

1. Harvey JC, Fleischman EH, Kagan AR, et al. Malignant pleural mesothelioma: a survival study. J Surg Oncol 1990;45:40-42.
2. Ceresoli GL, Locati LD, Ferreri AJM, et al. Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer 2001;34:279-287.
3. Aziz T, Jilaihawi A, Prakash D. The management of malignant pleural mesothelioma; single centre experience in 10 years. Eur J Cardiothorac Surg 2002;22:298-305.
4. Ruffie P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 1989;7:1157-1168.
5. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004;15:257-260.
6. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-214.
7. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
8. Browman GP, Levine MN, Mohide EA, et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995;13:502-512.
9. Lipsey MW, Wilson DB. Practical Meta-analysis. Thousand Oaks, CA: : Sage Publications, 2001. p. 113-116.
10. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23:6881-6889.
11. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21: 2636-2644.
12. O'Brien ME, Saini A, Smith IE, et al. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br J Cancer 2000;83:853-857.
13. White SC, Anderson H, Jayson GC, et al. Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma. Ann Oncol 2000;11:201-206.
14. Chahinian AP, Antman K, Goutsou M, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 1993;11:1559-1565.
15. Samson MK, Wasser LP, Borden EC, et al. Randomized comparison of cyclophosphamide, imidazole carboxamide, and Adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. J Clin Oncol 1987;5:86-91.
16. Cantwell BM, Franks CR, Harris AL. A phase II study of the platinum analogues JM8 and JM9 in malignant pleural mesothelioma. Cancer Chemother Pharmacol 1986;18:286-288.
17. Sorensen PG, Bach F, Bork E, et al. Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 1985;69:1431-1432.
18. van Meerbeeck JP, Baas P, Debruyne C, et al. A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma. Eur J Cancer 2002;38:779-783.
19. Andersen MK, Krarup-Hansen A, Martensson G, et al. Ifosfamide in malignant mesothelioma: a phase II study. Lung Cancer 1999;24:39-43.
20. Icli F, Karaoguz H, Hasturk S, et al. Two dose levels of ifosfamide in malignant mesothelioma. Lung Cancer 1996;15:207-213.
21. Falkson G, Hunt M, Borden EC, et al. An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. Invest New Drugs 1992;10:337-343.
22. Zidar BL, Metch B, Balcerzak SP, et al. A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study. Cancer 1992;70:2547-2551.
23. Alberts SR, Falkson G, Van Zyl L. Malignant pleural mesothelioma: phase II pilot study of ifosfamide and mesna. J Natl Cancer Inst 1988;80:698-700.
24. Anderson H, Haselton P, Michie AB, et al. 24-hour cyclophosphamide infusion therapy for malignant mesothelioma of the pleura. Br J Dis Chest 1988;82:64-69.
25. Steele JP, O'Doherty CA, Shamash J, et al. Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma. Ann Oncol 2001;12:497-499.
26. Baas P, van Meerbeeck J, Groen H, et al. Caelyx in malignant mesothelioma: a phase II EORTC study. Ann Oncol 2000;11:697-700.
27. Oh Y, Perez-Soler R, Fossella FV, et al. Phase II study of intravenous Doxil in malignant pleural mesothelioma. Invest New Drugs 2000;18:243-245.
28. Mattson K, Giaccone G, Kirkpatrick A, et al. Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1992;10:824-828.
29. Magri MD, Veronesi A, Foladore S, et al. Epirubicin in the treatment of malignant mesothelioma: a phase II cooperative study. The North-Eastern Italian Oncology Group (GOCCNE)-Mesothelioma Committee. Tumori 1991;77:49-51.
30. van Breukelen FJ, Mattson K, Giaccone G, et al. Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group. Eur J Cancer 1991;27:1627-1629.
31. Kaukel E, Koschel G, Gatzemeyer U, et al. A phase II study of pirarubicin in malignant pleural mesothelioma. Cancer 1990;66:651-654.
32. Eisenhauer EA, Evans WK, Raghavan D, et al. Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group Study. Cancer Treat Rep 1986;70:1029-1030.
33. Colbert N, Vannetzel JM, Izrael V, et al. A prospective study of detorubicin in malignant mesothelioma. Cancer 1985;56:2170-2174.
34. Harvey VJ, Slevin ML, Ponder BA, et al. Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and Adriamycin. Cancer 1984;54:961-964.
35. Vorobiof DA, Rapoport BL, Chasen MR, et al. Malignant pleural mesothelioma: a phase II trial with docetaxel. Ann Oncol 2002;13:412-415.
36. Belani CP, Adak S, Aisner S, et al. Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group (ECOG 2595) [abstract]. Proc Am Soc Clin Oncol 1999;18:A1829.
37. Vogelzang NJ, Herndon JE, Miller A, et al. High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. Ann Oncol 1999;10:597-600.
38. van Meerbeeck J, Debruyne C, van Zandwijk N, et al. Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 1996;74:961-963.
39. Steele JP, Shamash J, Evans MT, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000;18:3912-3917.
40. Martensson G, Sorenson S. A phase II study of vincristine in malignant mesothelioma - a negative report. Cancer Chemother Pharmacol 1989;24:133-134.
41. Cowan JD, Green S, Lucas J, et al. Phase II trial of five day intravenous infusion vinblastine sulfate in patients with diffuse malignant mesothelioma: a Southwest Oncology Group study. Invest New Drugs 1988;6:247-248.
42. Boutin C, Irisson M, Guerin JC, et al. Phase II trial of vindesine in malignant pleural mesothelioma. Cancer Treat Rep 1987;71:205-206.
43. Kelsen D, Gralla R, Cheng E, et al. Vindesine in the treatment of malignant mesothelioma: a phase II study. Cancer Treat Rep 1983;67:821-822.
44. Kindler HL, Millard F, Herndon JE, et al.Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Lung Cancer 2001;31:311-317.
45. van Meerbeeck JP, Baas P, Debruyne C, et al. A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer 1999;85:2577-2582.
46. Bischoff HG, Manegold C, Knopp M, et al. Gemcitabine (Gemzar® ) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma [abstract]. Proc Am Soc Clin Oncol 1998;17:A1784.
47. Baas P, Ardizzoni A, Grossi F, et al. The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). Eur J Cancer 2003;39:353-357.
48. Otterson GA, Herndon J, Watson D, et al. Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 39807) [abstract]. Proc Am Soc Clin Oncol 2003;22:A2778.
49. Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21:1556-1561.
50. Kindler HL, Belani CP, Herndon JE, et al. Edatrexate (10-ethyl- deazaaminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B. Cancer 1999;86:1985-1991.
51. Vogelzang NJ, Weissman LB, Herndon JE, et al. Trimetrexate in malignant mesothelioma: a cancer and leukemia group B phase II study. J Clin Oncol 1994;12:1436-1442.
52. Solheim OP, Saeter G, Finnanger AM, et al. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 1992;65:956-960.
53. Dimitrov NV, Egner J, Balcueva E, et al. High-dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma. Cancer 1982;50:1245-1247.
54. Kindler HL, Herndon JE, Vogelzang NJ, et al. CPT-11 in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 9733) [abstract]. Proc Am Soc Clin Oncol 2000;19:A1978.
55. Maksymiuk AW, Marschke RFJ, Tazelaar HD, et al. Phase II trial of topotecan for the treatment of mesothelioma. Am J Clin Oncol 1998;21:610-613.
56. Sahmoud T, Postmus PE, van Pottelsberghe C, et al. Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group. Eur J Cancer 1997;33:2211-2215.
57. Tammilehto L, Maasilta P, Mantyla M, et al. Oral etoposide in the treatment of malignant mesothelioma. A phase II study. Ann Oncol 1994;5:949-950.
58. Villano JL, Husain AN, Stadler WM, et al. A phase II trial of imatinib mesylate in patients (pts) with malignant mesothelioma (MM) [abstract]. Proc Am Soc Clin Oncol 2004;22:A7200.
59. Govindan R, Kratzke RA, Herndon JE, et al. Gefitinib in patients with malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B (CALGB 30101) [abstract]. Proc Am Soc Clin Oncol 2003;22:A2535.
60. Millward M, Parnis F, Byrne M, et al. Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma [abstract]. Proc Am Soc Clin Oncol 2003;22:A912.
61. Mikulski SM, Costanzi JJ, Vogelzang NJ, et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 2002;20:274-281.
62. Vogelzang NJ, Herndon JE, Cirrincione C, et al. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer 1997;79:2237-2242.
63. Hudis CA, Kelsen DP. Menogaril in the treatment of malignant mesothelioma: a phase II study. Invest New Drugs 1992;10:103-106.
64. Dhingra HM, Murphy WK, Winn RJ, et al. Phase II trial of 5,6-dihydro-5-azacytidine in pleural malignant mesothelioma. Invest New Drugs 1991;9:69-72.
65. Bajorin D, Kelsen D, Mintzer DM. Phase II trial of mitomycin in malignant mesothelioma. Cancer Treatment Rep 1987;71:857-858.
66. Falkson G, Vorobiof DA, Simson IW, et al. Phase II trial of acivicin in malignant mesothelioma. Cancer Treat Rep 1987;71:545-546.
67. Cantwell BM, Earnshaw M, Harris AL. Phase II study of a novel antifolate, N10-propargyl-5,8 dideazafolic acid (CB3717), in malignant mesothelioma. Cancer Treat Rep 1986;70:1335-1336.
68. Eagan RT, Frytak S, Richardson RL, et al. Phase II trial of diaziquone in malignant mesothelioma. Cancer Treat Rep 1986;70:429.
69. Falkson G, Vorobiof DA, Lerner HJ. A phase II study of m-AMSA in patients with malignant mesothelioma. Cancer Chemother Pharmacol 1983;11:94-97.
70. Okuno SH, Delaune R, Geyer S, et al. Gemcitabine and epirubicin in patients with malignant pleural mesothelioma (MPM): a North Central Cancer Treatment Group phase II study [abstract]. Proc Am Soc Clin Oncol 2003;22:A2802.
71. Baas P, van den Bongard D, Belbul M, et al. High dose methotrexate (HDMTX) with or without Adriamycin in malignant pleural mesothelioma (MPM): phase II clinical pharmacokinetic studies [abstract]. Proc Am Soc Clin Oncol 2002;21:A2733.
72. Dirix LY, van Meerbeeck J, Schrijvers D, et al. A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. Ann Oncol 1994;5:653-655.
73. Magri MD, Foladore S, Veronesi A, et al. Treatment of malignant mesothelioma with epirubicin and ifosfamide: a phase II cooperative study. Ann Oncol 1992;3:237-238.
74. Carmichael J, Cantwell BM, Harris AL. A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma. Eur J Cancer 1989;25:911-912.
75. Jett JR, Eagan RT. Chemotherapy for malignant mesothelioma; CAMEO. Am J Clin Oncol 1982;5:429-431.
76. Chahinian AP, Holland JF, Mandel EM. Chemotherapy for malignant mesothelioma with Adriamycin and continuous infusion of 5-azacytidine. Cancer Treat Rep 1978;62:1108-1109.
77. Janne PA, Obasaju C, Simon G, et al. A phase 2 clinical trial of pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural mesothelioma (MPM). Proc Am Soc Clin Oncol 2004;23:A7053.
78. Ferrari VD, Simoncini E, Marini G, et al. Gemcitabine (GEM) plus irinotecan (CPT11) in malignant mesothelioma (MM): a phase II study. Preliminary report. [abstract]. Proc Am Soc Clin Oncol 2002;21:A2755.
79. Pinto C, Marino A, Guaraldi M, et al. Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 2001;24:143-147.
80. Knuuttila A, Ollikainen T, Halme M, et al. Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma - a feasibility study. Anticancer Drugs 2000;11:257-261.
81. Gridelli C, Pepe R, Airoma G, et al. Mitomycin C and vindesine: an ineffective combination chemotherapy in the treatment of malignant pleural mesothelioma. Tumori 1992;78:380-382.
82. Planting AS, Schellens JH, Goey SH, et al. Weekly high-dose cisplatin in malignant pleural mesothelioma. Ann Oncol 1994;5:373-374.
83. Rebattu P, Merrouche Y, Blay JY, et al. Phase II study of very high dose cisplatin in the treatment of malignant mesothelioma. Eur Respir Rev 1993;3:226-228.
84. Zidar BL, Green S, Pierce HI, et al. A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study. Invest New Drugs 1988;6:223-226.
85. Markman M, Cleary S, Pfeifle C, et al. Cisplatin administered by the intracavity route as treatment for malignant mesothelioma. Cancer 1986;58:18-21.
86. Mintzer DM, Kelsen D, Frimmer D, et al. Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 1985;69:711-712.
87. Raghavan D, Gianoutsos P, Bishop J, et al. Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 1990;8:151-154.
88. Vogelzang NJ, Goutsou M, Corson JM, et al. Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol 1990;27:239-242.
89. Mbidde EK, Harland SJ, Calvert AH, et al. Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma. Cancer Chemother Pharmacol 1986;18:284-285.
90. Giaccone G, O'Brien ME, Byrne MJ, et al. Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur J Cancer 2002;38:S19-S24.
91. Hillerdal G, Sundstrom S, Sorensen JB. Malignant pleural mesothelioma treated with a combination of pegylated liposomal doxorubicin, carboplatin and gemcitabine: the CCG study [abstract]. Proc Am Soc Clin Oncol 2003;22:A2534.
92. Pennucci MC, Ardizzoni A, Pronzato P, et al. Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force. Cancer 1997;79:1897-1902.
93. Tomiak A, Vincent M, Kocha W, et al. Epirubicin and cisplatin chemotherapy for pleural mesothelioma [abstract]. Proc Am Soc Clin Oncol 1997;16:A1747.
94. Shin DM, Fossella FV, Umsawasdi T, et al. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer 1995;76:2230-2236.
95. Breau JL, Boaziz C, Morère JF, et al. Chemotherapy with cisplatin, Adriamycin, bleomycin and mitomycin C, combined with systemic and intrapleural hyaluronidase in stage II and III pleural mesothelioma. Eur Respir Rev 1993;3:223-225.
96. Ardizzoni A, Rosso R, Salvati F, et al. Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study. Cancer 1991;67:2984-2987.
97. Henss H, Feibeg HH, Schlidge J, et al. Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura. Onkologie 1988;11:118-120.
98. Bakhshandeh A, Bruns I, Traynor A, et al. Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma. Lung Cancer 2003;39:339-345.
99. Planting AS, van der Burg ME, Goey SH, et al. Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma. Ann Oncol 1995;6:613-615.
100. Eisenhauer EA, Evans WK, Murray N, et al. A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma. An NCI Canada Clinical Trials Group Study. Invest New Drugs 1988;6:327-329.
101. Middleton GW, Smith IE, O'Brien ME, et al. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 1998;9:269-273.
102. Tsavaris N, Mylonakis N, Karvounis N, et al. Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma. Lung Cancer 1994;11:299-303.
103. Castagneto B, Zai S, Dongiovanni V, et al. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study [abstract]. Proc Am Soc Clin Oncol 2003;22:A2637.
104. Favaretto AG, Aversa SM, Paccagnella A, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 2003;97:2791-2797.
105. Pinto C, Marino A, De Pangher Manzini V, et al. Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in untreated malignant pleural mesothelioma (MPM): a multicentric Italian phase II study (SITMP1) [abstract]. Proc Am Soc Clin Oncol 2003;22:A2613.
106. Nowak AK, Byrne MJ, Williamson R, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002;87:491-496.
107. Steele JP, Shamash J, Barlow CS, et al. Phase II trial of irinotecan, cisplatin and mitomycin C (IPM) in malignant pleural mesothelioma (MPM) [abstract]. Proc Am Soc Clin Oncol 2002;21:A1227.
108. Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999;17:25-30.
109. Kasseyet S, Astoul P, Boutin C. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura. Cancer 1999;85:1740-1749.
110. Nakano T, Chahinian AP, Shinjo M, et al. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile. Cancer 1999;85:2375-2384.
111. Samuels BL, Herndon JE, Harmon DC, et al. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Cancer 1998;82:1578-1584.
112. Fizazi K, Doubre H, Le Chevalier T, et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol 2003;21:349-354.
113. Schuette W, Blankenburg T, Lauerwald K, et al. A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clin Lung Cancer 2003;4:294-297.
114. Steele JPC, Shamash J, Evans MT, et al. Phase II trial of vinorelbine and oxaliplatin ('VO') in malignant pleural mesothelioma (MPM) [abstract]. Proc Am Soc Clin Oncol 2001;20:A1335.
115. Aitini E, Cavazzini G, Pasquini E, et al. Treatment of primary or metastatic pleural effusion with intracavitary cytosine arabinoside and cisplatin. A phase II study. Acta Oncol 1994;33:191-194.
116. Bednar ME, Chahinian P. Paclitaxel and carboplatin for malignant mesothelioma [abstract]. Proc Am Soc Clin Oncol 1999;18:A1916.
117. Halme M, Knuuttila A, Vehmas T, et al. High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma. Br J Cancer 1999;80:1781-1785.
118. Bretti S, Berruti A, Dogliotti L, et al. Combined epirubicin and interleukin-2 regimen in the treatment of malignant mesothelioma: a multicenter phase II study of the Italian Group on Rare Tumors. Tumori 1998;84:558-561.
119. Upham JW, Musk AW, van Hazel G, et al. Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study. Aust N Z J Med 1993;23:683-687.
120. O'Reilly EM, Ilson DH, Saltz LB, et al. A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma. Cancer Invest 1999;17:195-200.
121. Purohit A, Moreau L, Dietemann A, et al. Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma. Lung Cancer 1998;22:119-125.
122. Trandafir L, Ruffie P, Borel C, et al. Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma. Eur J Cancer 1997;33:1900-1902.
123. Soulie P, Ruffie P, Trandafir L, et al. Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a. J Clin Oncol 1996;14:878-885.
124. Pass HW, Temeck BK, Kranda K, et al. A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction. Ann Surg Oncol 1995;2:214-220.
125. Parra HS, Tixi L, Latteri F, et al. Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP). Cancer 2001;92:650-656.
126. Metintas M, Ozdemir N, Ucgun I, et al. Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma. Chest 1999;116:391-398.
127. Hasturk S, Tastepe I, Unlu M, et al. Combined chemotherapy in pleurectomized malignant pleural mesothelioma patients. J Chemother 1996;8:159-164.
128. Tansan S, Emri S, Selcuk T, et al. Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon. Oncology 1994;51:348-351.
129. British Thoracic Society Standards of Care Committee. Statement on malignant mesothelioma in the United Kingdom. Thorax 2001;56:250-265.
130. Berghmans T, Paesmans M, Lalami Y, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002;38:111-121.
131. Vogelzang NJ, Rusthoven J, Paoletti P, et al. Phase III single-blinded study of pemetrexed + cisplatin vs. cisplatin alone in chemonaive patients with malignant pleural mesothelioma [abstract]. Proc Am Soc Clin Oncol 2002;21:A5.
132. Vogelzang NJ, Rusthoven J, Paoletti P, et al. Phase III single-blinded study of pemetrexed + cisplatin vs. cisplatin alone in chemonaive patients with malignant pleural mesothelioma [slide presentation on Internet]. ASCO.org Virtual Meeting. 2002. Available at: http://www.asco.org/portal/site/ASCO/ menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID= 16&abstractID=5. Accessed June 4, 2005.
133. O'Brien ME, Watkins D, Ryan C, et al. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 2006;17:270-275.